Chinese clinical-stage biopharmaceutical company InventisBio Inc. announced that the company has grabbed $70 million in funding round.
Advantech Capital and CMB International Capital Corp. co-led the Series C round. Other backers including Pudong Innotek and existing investors Lilly Asia Venture and OrbiMed Asia also joined the round.
With the net funds, InventisBio will advance the development of its clinical candidates into phase 2 trials and develop drug candidates into clinical stage.
In 2017, InventisBio also closed Series B funding led by OrbiMed Asia with participation from Lilly Asia Venture.